全文获取类型
收费全文 | 893篇 |
免费 | 95篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 42篇 |
妇产科学 | 18篇 |
基础医学 | 121篇 |
口腔科学 | 20篇 |
临床医学 | 82篇 |
内科学 | 128篇 |
皮肤病学 | 23篇 |
神经病学 | 38篇 |
特种医学 | 140篇 |
外科学 | 181篇 |
综合类 | 27篇 |
预防医学 | 52篇 |
眼科学 | 16篇 |
药学 | 55篇 |
中国医学 | 2篇 |
肿瘤学 | 35篇 |
出版年
2021年 | 12篇 |
2020年 | 9篇 |
2019年 | 9篇 |
2018年 | 14篇 |
2017年 | 9篇 |
2016年 | 18篇 |
2015年 | 26篇 |
2014年 | 17篇 |
2013年 | 20篇 |
2012年 | 27篇 |
2011年 | 41篇 |
2010年 | 32篇 |
2009年 | 37篇 |
2008年 | 25篇 |
2007年 | 43篇 |
2006年 | 35篇 |
2005年 | 32篇 |
2004年 | 25篇 |
2003年 | 23篇 |
2002年 | 15篇 |
2001年 | 28篇 |
2000年 | 17篇 |
1999年 | 9篇 |
1998年 | 23篇 |
1997年 | 37篇 |
1996年 | 30篇 |
1995年 | 30篇 |
1994年 | 21篇 |
1993年 | 9篇 |
1992年 | 15篇 |
1991年 | 11篇 |
1990年 | 19篇 |
1989年 | 23篇 |
1988年 | 22篇 |
1987年 | 24篇 |
1986年 | 23篇 |
1985年 | 18篇 |
1984年 | 11篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 15篇 |
1979年 | 6篇 |
1977年 | 19篇 |
1976年 | 13篇 |
1975年 | 6篇 |
1973年 | 6篇 |
1971年 | 10篇 |
1970年 | 7篇 |
1969年 | 6篇 |
排序方式: 共有1001条查询结果,搜索用时 15 毫秒
11.
12.
Life expectancy in British Marfan syndrome populations 总被引:2,自引:0,他引:2
JR Gray AB Bridges RR West L. McLeish AG Stuart JCS Dean MEM Porteous M. Boxer SJ Davies 《Clinical genetics》1998,54(2):124-128
A total of 206 patients with Marfan syndrome were ascertained throughout genetic clinics in Wales and Scotland during the period 1970–1990. There were 45 deaths representing 22% of the cohort. Mean age at death was 45.3 ± 16.5 years. 50% median cumulative survival in the total cohort (n = 206) was 53 years for males and 72 years for females. Multivariate analysis confirmed severity as the best independent indicator of survival. These findings and survival curves will assist in the counselling of British families and individuals with Marfan syndrome. 相似文献
13.
14.
David W Dempster Hua Zhou Sudhaker D Rao Chris Recknor Paul D Miller Benjamin Z Leder Miriam Annett Michael S Ominsky Bruce H Mitlak 《Journal of bone and mineral research》2021,36(4):644-653
Anabolic osteoporosis drugs improve bone mineral density by increasing bone formation. The objective of this study was to evaluate the early effects of abaloparatide on indices of bone formation and to assess the effect of abaloparatide on modeling-based formation (MBF), remodeling-based formation (RBF), and overflow MBF (oMBF) in transiliac bone biopsies. In this open-label, single-arm study, 23 postmenopausal women with osteoporosis were treated with 80 μg abaloparatide daily. Subjects received double fluorochrome labels before treatment and before biopsy collection at 3 months. Change in dynamic histomorphometry indices in four bone envelopes were assessed. Median mineralizing surface per unit of bone surface (MS/BS) increased to 24.7%, 48.7%, 21.4%, and 16.3% of total surface after 3 months of abaloparatide treatment, representing 5.5-, 5.2-, 2.8-, and 12.9-fold changes, on cancellous, endocortical, intracortical, and periosteal surfaces (p < .001 versus baseline for all). Mineral apposition rate (MAR) was significantly increased only on intracortical surfaces. Bone formation rate (BFR/BS) was significantly increased on all four bone envelopes. Significant increases versus baseline were observed in MBF on cancellous, endocortical, and periosteal surfaces, for oMBF on cancellous and endocortical surfaces, and for RBF on cancellous, endocortical, and intracortical surfaces. Overall, modeling-based formation (MBF + oMBF) accounted for 37% and 23% of the increase in bone-forming surface on the endocortical and cancellous surfaces, respectively. Changes from baseline in serum biomarkers of bone turnover at either month 1 or month 3 were generally good surrogates for changes in histomorphometric endpoints. In conclusion, treatment with abaloparatide for 3 months stimulated bone formation on cancellous, endocortical, intracortical, and periosteal envelopes in transiliac bone biopsies obtained from postmenopausal women with osteoporosis. These increases reflected stimulation of both remodeling- and modeling-based bone formation, further elucidating the mechanisms by which abaloparatide improves bone mass and lowers fracture risk. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). 相似文献
15.
Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. 下载免费PDF全文
V Shen R Birchman R Xu M Otter D Wu R Lindsay D W Dempster 《The Journal of clinical investigation》1995,96(5):2331-2338
Intermittent administration of PTH has been found to be an effective anabolic agent in cancellous bone. We have reported previously that combined treatment with PTH and estrogen in estrogen-deficient rats was beneficial in correcting established osteopenia. To determine if the beneficial effects of PTH therapy can be preserved by estrogen alone and whether PTH therapy can be effective in treating osteopenic subjects stabilized with estrogen, we have undertaken a "crossover" study in the rat model of estrogen-deficiency induced osteopenia. Six-month-old female rats were ovariectomized and after 5 wk treated for 8 wk with vehicle, 30 micrograms/kg per day of rPTH(1-34) plus 15 micrograms/kg per day of 17 beta-estradiol or 17 beta-estradiol alone. One group from each treatment regimen was then sacrificed and for an additional 8 weeks the remaining rats were (a) maintained on their previous treatment; (b) "crossed over" to their reciprocal treatment; or (c) administered vehicle only. At the end of this second 8-wk treatment period all rats were sacrificed. Bone mineral density of the distal femur, histomorphometric measurements of the proximal tibia and mechanical testing of the distal femur and selected vertebral bodies were performed. Our results demonstrated that (a) the gains in bone mass, trabecular connectivity and mechanical strength induced by PTH can be maintained by estrogen alone, but are reversed when both agents are withdrawn; and (b) rats with established osteopenia, maintained on estrogen treatment alone, can derive the full beneficial effects from the addition of PTH to the treatment at a later date. These data indicate that combined and/or sequential use of antiresorptive and anabolic agents may be a promising approach to the treatment of osteoporosis. 相似文献
16.
17.
Molteno implants: the principles of bleb management 总被引:1,自引:0,他引:1
Molteno AC Dempster AG Carne A 《Australian and New Zealand journal of ophthalmology》1999,27(5):350-352
18.
Paulo CJL Santos Renata AG Soares Diogo BG Santos Raimundo M Nascimento George LLM Coelho José C Nicolau José G Mill José E Krieger Alexandre C Pereira 《BMC medical genetics》2011,12(1):13
Background
Recent studies have reported the clinical importance of CYP2C19 and ABCB1 polymorphisms in an individualized approach to clopidogrel treatment. The aims of this study were to evaluate the frequencies of CYP2C19 and ABCB1 polymorphisms and to identify the clopidogrel-predicted metabolic phenotypes according to ethnic groups in a sample of individuals representative of a highly admixtured population. 相似文献19.
Zielinsky A; Hirsh J; Straumanis G; Carter CJ; Gent M; Sackett DL; Hull R; Kelton JG; Powers P; Turpie AG 《Blood》1982,59(2):346-350
We have evaluated the fibrinogen/fibrin fragment E antigen assay as a diagnostic test in patients with clinically suspected venous thrombosis by comparing the results of this assay with venography in 272 patients. The result of the fragment E antigen assay was elevated in 79 of 80 patients with positive venograms for recent venous thrombosis (sensitivity 99%) and within the normal range in 161 of 192 patients with normal venograms (specificity 84%). The fragment E assay was also evaluated in 130 medical and surgical controls without evidence of venous thrombosis by leg scanning and the test was found to be relatively nonspecific. However, in the patient group under study, a correct clinical diagnosis of no thrombosis, based on a normal fragment E result, was made in 161 of 162 cases (negative predictive value of 99%). Therefore, a normal test result effectively excludes a diagnosis of venous thrombosis in clinically symptomatic patients. The assay, as currently performed, is technically demanding and takes 24 hr to complete. Therefore, it will have to be simplified before it can be applied to clinical practice. 相似文献
20.